Brensocatib, newly approved by the FDA for noncystic fibrosis bronchiectasis (NCFB), was also associated with improvements in lung structure, on the basis of data from a substudy of 100 individuals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback